MONTEVIDEO, Uruguay, Dec. 15, 2017 — BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that has hired Ivan French as Executive Vice President of Research and Development.
Ivan French has a long career combining medicine and management, having been for example a Medical Team Leader at Medicines sans Frontiers, a clinical research fellow at Genzyme Corporation but also an investment banker with Morgan Stanley New York and most recently, the General Manager for Uber Uruguay. Ivan will lead GBT´s proprietary products development efforts, taking over the company's research center in Argentina and its recently acquired DOSA research center. Together with Renato De Giorgi, head of Business Development and Daniel Flores, Sr. Science Advisor, Ivan will lead the company's pipeline strategy. Ivan French has a Medical Doctor Degree (Magna cum Laude) from Universidad Austral and an MBA from Harvard Business School.
According to Mariano Garcia-Valiño, CEO of GBT, “Ivan will bring renewed efforts into our proprietary product and clinical development and enhance our abilities to reach further-up into the R&D chain into earlier development phases, where more promising products and rarer opportunities are available.”
Mr. French will be responsible for GBT's clinical research teams, central regulatory teams and central pharmacovigilance teams, both legacy LKM and legacy DOSA.
About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT's strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.
GBT – Grupo Biotoscana
+55 11 5090 5927
SOURCE Grupo Biotoscana
Latest posts by Maria Burns (see all)
- BestVPN.co Marks Its Entrance Into the Realm of Digital Privacy and Security - February 22, 2018
- San Buenaventura Urology Honored as Fourth Practice Nationwide To Have Two Physicians Designated as UroLift Center of Excellence - February 22, 2018
- Vendor Risk Management Market to Grow at 14.6% CAGR to 2022 - February 22, 2018